The combined effects of tick defensin persulcatusin with conventional antibiotics and antimicrobial proteins/peptides against Staphylococcus aureus

蜱防御素全沟素与传统抗生素和抗菌蛋白/肽联合使用对抗金黄色葡萄球菌的效果

阅读:1

Abstract

Persulcatusin (IP) is a tick defensin isolated from Ixodes persulcatus and is composed of 38 aa (molecular weight of 4,200). IP exhibits potent antimicrobial activity against Staphylococcus aureus, including drug-resistant strains, such as methicillin- and vancomycin-resistant S. aureus. Despite its potential use as an anti-S. aureus drug, its application remains underdeveloped because of several limitations, such as manufacturing costs and in vivo safety. Here, the combined effect of IP and other conventional antibiotics and antimicrobial proteins/peptides against S. aureus bacterial infections was investigated. Combinations of several antimicrobial compounds, including β-lactams, peptide antibiotics and lytic enzymes, showed a synergistic effect against S. aureus with a fractional inhibitory concentration index (FICI) of ≤0.75. In contrast, IP had an additive or irrelevant effect with a FICI of 1.0-2.0 when combined with several antibiotics such as chloramphenicol, gentamycin, kanamycin, erythromycin or vancomycin. Interestingly, S. aureus cells pretreated with IP for a short time demonstrated reduced susceptibility to daptomycin. Furthermore, it was determined that the mode of bactericidal activity of IP was substantially different in growth and non-growth states, suggesting that the mechanism of action of IP was associated with the inhibition of bacterial biosynthesis. These findings indicated that the combined effect of IP and conventional antibiotics has the potential to be used as an effective antimicrobial drug against S. aureus. Furthermore, it also suggested that an unknown mechanism of action of IP was associated with the inhibition of bacterial cell biosynthesis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。